For the six months ended December 2026, consolidated net sales were 6,932 million yen (up 5.6% YoY), operating income 336 million yen (\u25b338.6%), ordinary income 398 million yen (\u25b324.2%), and net income attributable to owners of the parent 260 million yen (\u25b337.0% YoY), with a decline in profitability despite growth in in-house sales. While product sales increased, rising costs and overseas market development expenses pressured profits. The year-end dividend forecast remains unchanged, and the full-year earnings forecast has already been revised in the press release.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"5187","jir_company_name":"Create Medic Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/5187-20260805-01.pdf","jir_short_summary":"For the six months ended December 2026, consolidated net sales were 6,932 million yen (up 5.6% YoY), operating income 336 million yen (\u25b338.6%), ordinary income 398 million yen (\u25b324.2%), and net income attributable to owners of the parent 260 million yen (\u25b337.0% YoY), with a decline in profitability despite growth in in-house sales. While product sales increased, rising costs and overseas market development expenses pressured profits. The year-end dividend forecast remains unchanged, and the full-year earnings forecast has already been revised in the press release.","jir_summary":"### Overview of results\nAlthough in-house sales grew steadily, profits were significantly reduced due to higher cost of sales and increased overseas market development expenses. New products in the urology segment contributed to sales, but currency effects and elevated raw material prices squeezed profits. Net sales rose 5.6% year over year to 6,932 million yen, operating income declined 38.6% to 336 million yen, and net income attributable to owners of the parent fell 37.0% to 260 million yen.\n\n### Outlook and financial position\nFull-year earnings guidance has been revised, see the notice titled \u2018Difference between the second-quarter (interim) earnings forecast and actual results and revision of the full-year consolidated earnings forecast.\u2019 The timing of the dividend payment and the expected year-end dividend remain unchanged, but there is no change to the latest dividend forecast. Cash and cash equivalents at year-end were 4,936\u767e\u4e07\u5186, and attention should be paid to shareholder equity movements including treasury stock acquisitions.","jir_financial_highlights":"Sales: 6,932\u767e\u4e07\u5186 (YoY +5.6%)\nOperating income: 336\u767e\u4e07\u5186 (YoY \u25b338.6%)\nOrdinary income: 398\u767e\u4e07\u5186 (YoY \u25b324.2%)\nNet income attributable to owners of the parent (interim): 260\u767e\u4e07\u5186 (YoY \u25b337.0%)\nEquity ratio: 81.9% (No change from previous term)","jir_category":"","jir_hashtags":"#CreateMedic, #FinancialResults, #JapanStocks","jir_key_figures":"Sales: 6,932\u767e\u4e07\u5186 (YoY +5.6%)\nOperating income: 336\u767e\u4e07\u5186 (YoY \u25b338.6%)\nNet income attributable to owners of the parent (interim): 260\u767e\u4e07\u5186 (YoY \u25b337.0%)","jir_meta_title":"\u3010Create Medic\u3011FY2026 Interim Results for the Six Months Ended December 2026 | Sales 6,932 million yen; Net income 260 million yen","jir_meta_description":"Highlights of Create Medic's interim results for the six months ended December 2026. Summary of sales and earnings, segment trends, and revisions to full-year guidance. Dividend outlook maintained.","jir_og_title":"\u3010Create Medic\u3011Key Points of the FY2026 Interim Results","jir_og_description":"Interim period sales were 6,932 million yen, operating income 336 million yen. Analyzing the impacts of new product introductions and cost increases. Outlook and dividend policy discussed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59045,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95490","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n